JELINEK, Tomas, Tereza SEVCIKOVA, David ZIHALA, Tereza POPKOVA, Veronika KAPUSTOVA, Lucie BROSKEVICOVA, Lenka CAPKOVA, Lucie ŘÍHOVÁ, Renata BEZDĚKOVÁ, Sabina ŠEVČÍKOVÁ, Vladimir ZIDLIK, Martin HAVEL, Hana PLONKOVA, Alexandra JUNGOVA, Jiri MINARIK, Martin ŠTORK, Luděk POUR, Petr PAVLICEK, Ivan SPICKA, Vladimir MAISNAR, Jakub RADOCHA, Michal SIMICEK and Roman HAJEK. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. London: Nature Publishing Group, 2022, vol. 36, No 1, p. 288-291. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01343-w.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
Authors JELINEK, Tomas (203 Czech Republic, guarantor), Tereza SEVCIKOVA (203 Czech Republic), David ZIHALA (203 Czech Republic), Tereza POPKOVA (203 Czech Republic), Veronika KAPUSTOVA (203 Czech Republic), Lucie BROSKEVICOVA (203 Czech Republic), Lenka CAPKOVA (203 Czech Republic), Lucie ŘÍHOVÁ (203 Czech Republic), Renata BEZDĚKOVÁ (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Vladimir ZIDLIK (203 Czech Republic), Martin HAVEL (203 Czech Republic), Hana PLONKOVA (203 Czech Republic), Alexandra JUNGOVA (203 Czech Republic), Jiri MINARIK (203 Czech Republic), Martin ŠTORK (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), Petr PAVLICEK (203 Czech Republic), Ivan SPICKA (203 Czech Republic), Vladimir MAISNAR (203 Czech Republic), Jakub RADOCHA (203 Czech Republic), Michal SIMICEK (203 Czech Republic) and Roman HAJEK (203 Czech Republic).
Edition Leukemia, London, Nature Publishing Group, 2022, 0887-6924.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 11.400
RIV identification code RIV/00216224:14110/22:00124970
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/s41375-021-01343-w
UT WoS 000671626300001
Keywords in English daratumumab; multiple myeloma; extramedullary disease; efficacy
Tags 14110212, 14110518, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 16/5/2022 08:59.
Abstract
The treatment of multiple myeloma (MM) has changed substantially during the past two decades. The incorporation of novel agents into therapeutic strategies has resulted in prolonged overall survival of MM patients with approximately 15% of them being considered operationally cured.
Links
LM2018140, research and development projectName: e-Infrastruktura CZ (Acronym: e-INFRA CZ)
Investor: Ministry of Education, Youth and Sports of the CR
NV17-29343A, research and development projectName: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu
PrintDisplayed: 21/7/2024 06:29